Skip to main content
SpringerLink
Log in

Antiresorptives

  • Chapter
Musculoskeletal Research and Basic Science

  • 2390 Accesses

Abstract

Antiresorptives are frequently used for the treatment of osteoporosis. They include bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab [antireceptor activator nuclear kappa-B ligand (RANKL) antibody], and calcitonin. They suppress excessive bone resorption, increase bone mineral density, and prevent fragility fractures. Side effects of long-term treatment with bisphosphonates or denosumab are osteonecrosis of the jaw and atypical femoral fractures. There are currently no clear conclusions to suggest how long antiresorptives remain beneficial and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Robinson CM, Royds M, Abraham A et al (2002) Refractures in patients at least forty-five years old. A prospective analysis of twenty-two thousand and sixty patients. J Bone Joint Surg Am 84:1528–1533

    Article  PubMed  Google Scholar 

  2. Papapoulos SE, Quandt SA, Liberman UA et al (2005) Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468–474

    Article  CAS  PubMed  Google Scholar 

  3. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Article  CAS  PubMed  Google Scholar 

  4. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  5. Osaki M, Tatsuki K, Hashikawa T et al (2012) Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23:695–703

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Black DM, Bauer DC, Schwartz AV et al (2012) Continuing bisphosphonate treatment for osteoporosis–for whom and for how long? N Engl J Med 366:2051–2053

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199

    Article  CAS  PubMed  Google Scholar 

  8. Wells GA, Cranney A, Peterson J et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1, CD001155

    PubMed  Google Scholar 

  9. Hagino H (2009) New development in bisphosphonate treatment. Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis. Clin Calcium 19:75–84

    CAS  PubMed  Google Scholar 

  10. Cranney A, Guyatt G, Griffith L et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578

    Article  CAS  PubMed  Google Scholar 

  11. Cranney A, Tugwell P, Adachi J et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523

    Article  CAS  PubMed  Google Scholar 

  12. Wells GA, Cranney A, Peterson J et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1, CD004523

    PubMed  Google Scholar 

  13. Bauss F, Russell RG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423–433

    Article  CAS  PubMed  Google Scholar 

  14. Fleish H (2000) Actions. Bisphosphonates in bone disease, 4th edn. Academic, New York, pp 34–55

    Book  Google Scholar 

  15. Matsumoto T, Hagino H, Shiraki M et al (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  17. Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967

    Article  PubMed Central  PubMed  Google Scholar 

  18. Wells GA, Cranney A, Peterson J et al (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1, CD003376

    PubMed  Google Scholar 

  19. Solomon DH, Mercer E, Woo SB et al (2013) Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int 24:237–244

    Article  CAS  PubMed  Google Scholar 

  20. Lee SH, Chan RC, Chang SS et al (2014) Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies. Support Care Cancer 22:553–560

    Article  PubMed  Google Scholar 

  21. Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  PubMed  Google Scholar 

  22. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916

    Article  CAS  PubMed  Google Scholar 

  23. Katzenellenbogen BS, Katzenellenbogen JA (2002) Biomedicine. Defining the “S” in SERMs. Science 295:2380–2381

    Article  CAS  PubMed  Google Scholar 

  24. Lippman ME, Cummings SR, Disch DP et al (2006) Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 12:5242–5247

    Article  CAS  PubMed  Google Scholar 

  25. Bone HG, Chapurlat R, Brandi ML et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Nakamura T, Matsumoto T, Sugimoto T et al (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Ikegame M, Ejiri S, Ozawa H (1994) Histochemical and autoradiographic studies on elcatonin internalization and intracellular movement in osteoclasts. J Bone Miner Res 9:25–37

    Article  CAS  PubMed  Google Scholar 

  28. Katae Y, Tanaka S, Sakai A et al (2009) Elcatonin injections suppress systemic bone resorption without affecting cortical bone regeneration after drill-hole injuries in mice. J Orthop Res 27:1652–1658

    Article  CAS  PubMed  Google Scholar 

  29. Braga PC (1994) Calcitonin and its antinociceptive activity: animal and human investigations 1975–1992. Agents Actions 41:121–131

    Article  CAS  PubMed  Google Scholar 

  30. Ito A, Kumamoto E, Takeda M et al (2000) Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci 20:6302–6308

    CAS  PubMed  Google Scholar 

  31. Shibata K, Takeda M, Ito A et al (1998) Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol Biochem Behav 60:371–376

    Article  CAS  PubMed  Google Scholar 

  32. Takayama B, Kikuchi S, Konno S et al (2008) An immunohistochemical study of the antinociceptive effect of calcitonin in ovariectomized rats. BMC Musculoskelet Disord 15:164

    Article  Google Scholar 

  33. Chesnut CH 3rd, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–276

    Article  CAS  PubMed  Google Scholar 

  34. O’Donnell S, Cranney A, Wells GA et al (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 3, CD005326

    PubMed  Google Scholar 

  35. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  36. Smith MR, Egerdie B, Hernández Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Kaufman JM, Audran M, Bianchi G et al (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98:592–601

    Article  CAS  PubMed  Google Scholar 

  38. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  CAS  PubMed  Google Scholar 

  39. Kaufman JM, Orwoll E, Goemaere S et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516

    Article  CAS  PubMed  Google Scholar 

  40. Sakai A, Ikeda S, Okimoto N et al (2014) Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporos Int 25:2245–2253

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Boonen S, Ferrari S, Miller PD et al (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 27:963–974

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    Akinori Sakai MD, PhD

Authors
  1. Akinori Sakai MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akinori Sakai MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Sports Medicine, Hacettepe University Medical Faculty, Ankara, Turkey

    Feza Korkusuz

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sakai, A. (2016). Antiresorptives. In: Korkusuz, F. (eds) Musculoskeletal Research and Basic Science. Springer, Cham. https://doi.org/10.1007/978-3-319-20777-3_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20777-3_42

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20776-6

  • Online ISBN: 978-3-319-20777-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation